Cobrek Pharmaceuticals

perrigo

Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam

Perrigo Co. (Nasdaq: PRGO) Tuesday announced that its partner, Cobrek Pharmaceuticals Inc., received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for betamethasone valerate foam 0.12 percent, the generic equivalent of Luxiq Foam.

WWJ Newsradio 950–11/27/2012

Follow

Get every new post delivered to your Inbox.

Join 2,477 other followers